RxDoctor Payments Data

Hailegiorgis Bizuneh

Psychiatric/Mental Health · Glen Allen, VANPI 1417528225

Payments from drug & device makers

$2,267in general payments, 2019–2025

Across 115 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$695
  • Neurocrine Biosciences, Inc.$262
  • Otsuka America Pharmaceutical, Inc.$174
  • Takeda Pharmaceuticals U.S.A., Inc.$145
  • Teva Pharmaceuticals USA, Inc.$140
  • E.r. Squibb & Sons, L.L.C.$134
  • plus $717 from 14 others

What the payments were for

  • Food & beverage$2,23198%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,267 in reported general payments places this provider in the 80th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$16,992
Medicare patients
35
Services billed
211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole13$36,268
VraylarCariprazine Hcl24$35,170
Ziprasidone Hcl20$3,498
Risperidone ErRisperidone Microspheres11$2,786
Aripiprazole30$1,924
Hydroxyzine Hcl60$1,284
Oxcarbazepine29$1,178
Paroxetine CrParoxetine Hcl11$1,112
Naltrexone Hcl12$985
Trazodone Hcl107$646
Quetiapine Fumarate47$605
Risperidone34$576
Bupropion XlBupropion Hcl42$449
Propranolol Hcl14$407
Lurasidone Hcl13$362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$174$36,26813 claims
AbbVieVraylar$695$35,17024 claims
Almatica Pharma LLCSertraline Hcl$50$35748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Glen Allen

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →